Qualigen Therapeutics, Inc.
(NASDAQ : QLGN)

( )
QLGN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
SAVACassava Sciences, Inc. -0.26%49.850.0%$181.10m
HZNPHorizon Therapeutics Plc 0.00%104.055.4%$171.46m
VRXValeant Pharmaceuticals International, Inc. 0.08%25.4214.1%$149.57m
CTLTCatalent, Inc. 0.02%127.482.0%$133.98m
ICLRICON plc 0.00%278.402.8%$111.31m
CPIXCumberland Pharmaceuticals, Inc. -1.56%5.690.6%$82.77m
JAZZJazz Pharmaceuticals Plc 0.00%126.112.1%$80.79m
UTHRUnited Therapeutics Corp. 0.00%193.9413.9%$71.35m
ARGXargenx SE -0.99%306.440.0%$67.71m
PRGOPerrigo Co. Plc -1.23%37.046.9%$65.74m
BHCBausch Health Cos., Inc. 0.08%25.420.0%$59.76m
ENDPEndo International Plc 0.00%5.268.5%$31.68m
CORTCorcept Therapeutics, Inc. 0.00%18.235.5%$28.92m
PCRXPacira Biosciences, Inc. 0.00%58.629.8%$27.90m
IRWDIronwood Pharmaceuticals, Inc. 0.00%11.449.5%$26.85m

Company Profile

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.